Home›OB/GYN & Women's Health› Progestin-only subdermal implants linked to 23% higher breast cancer risk in younger women
Progestin-only subdermal implants linked to 23% higher breast cancer risk in younger womenProgestin Only Subdermal Implants Linked to Higher Breast Cancer Risk
Cancer epidemiologyPublished August 2, 2026Study authors: Yabrude Angela Theresa Zuffo, Reis Leila Caroline Souza, Anchía Anthony Josué Rojas, Dos Santos Thom…PubMed ↗DOI ↗Editorial oversight: Dr. Sofia Müller, MD · Lifespan & Whole-Person Care
AI-generated summary of the cited source, checked by automated accuracy review.
How we work
Share
Key Takeaway
Consider discussing the small absolute breast cancer risk with progestin-only implants, especially in high-risk patients.
This meta-analysis synthesizes evidence from observational cohort and case-control studies to evaluate the association between progestin-only subdermal implants and incident breast cancer risk in adolescents and premenopausal women without prior breast cancer. The analysis included 1659,309 person-years of implant exposure and 67,470 cases from the case-control dataset. The pooled effect estimate showed a higher incident breast cancer risk with implant exposure (OR 1.23, 95% CI 1.19-1.27, p < 0.0001).
The primary outcome was incident breast cancer, including invasive with or without in situ disease. The comparator was non-use of hormonal contraception. The authors note that the association is based on observational data, so causality cannot be established. The absolute risk impact is likely small because the baseline incidence of breast cancer in younger women is low, as acknowledged in the limitations.
Safety outcomes such as adverse events, serious adverse events, and discontinuations were not reported in this meta-analysis. The authors did not report funding or conflicts of interest. The certainty of the evidence was not explicitly graded.
The findings are decision-relevant for shared contraceptive counseling, particularly in patients with elevated baseline breast cancer risk. Clinicians should weigh the potential small absolute risk increase against the benefits of effective contraception, and consider individual risk factors when discussing contraceptive options.
How this fits prior evidence
This meta-analysis extends prior coverage on breast cancer risk factors by quantifying the association between progestin-only subdermal implants and breast cancer risk. It complements earlier findings on diagnostic accuracy (FNAC with WHO system: 87.01% accuracy) and survival outcomes (Ghana: median OS 4.4 years) by addressing a modifiable exposure. The observed OR of 1.23 aligns with the modest risk increases seen with other hormonal contraceptives, but contrasts with the lack of risk data in prior coverage. It also addresses a gap by focusing on younger women, a group often underrepresented in breast cancer research.
Researchers looked at the link between progestin only subdermal implants and breast cancer. They focused on adolescents and premenopausal women who had not previously been diagnosed with breast cancer. The study combined data from several different sources to see if there was a pattern of risk associated with this specific type of hormonal contraception.
The analysis found that women using these implants had a higher risk of developing invasive breast cancer compared to those not using hormonal contraception. However, it is important to note that the actual number of cases may be small because breast cancer is less common in younger women. The study shows an association rather than a direct cause.
This information can help doctors give better advice when discussing birth control options. Patients with a higher baseline risk for breast cancer may find this information especially helpful during their consultations. You should talk to your healthcare provider to discuss how these findings apply to your personal health and history.
What this means for you:
Progestin only subdermal implants are linked to a higher risk of breast cancer in some women.
Common questions
Is the risk of breast cancer from these implants very high?
The study found an increased risk, but the actual impact may be small because breast cancer is less common in younger women. The data shows a link rather than a direct cause. You should speak with your doctor to understand how this specific risk applies to your personal health history.
Who is most affected by this finding?
The study specifically looked at adolescents and premenopausal women who had not previously been diagnosed with breast cancer. This information is particularly relevant for patients who may already have a higher baseline risk for breast cancer when choosing birth control.
How does this affect my choice of birth control?
This finding is intended to help doctors provide better counseling during consultations. It helps patients and providers weigh the risks and benefits of different contraceptive options based on individual health needs.
Long-acting reversible contraception with progestin-only subdermal implants is widely adopted. However, the breast cancer (BC) risk signal attributable to implants remains under-characterized, limiting evidence-based counseling. We systematically searched PubMed/MEDLINE, Embase, and Scopus,and screened references for observational cohort and case-control studies evaluating progestin-only implant versus non-use hormonal contraception in adolescents and premenopausal women without prior BC. The primary endpoint was incident BC (invasive with/without in situ, per study definition). Maximally adjusted effect estimates were extracted; measures were harmonized to odds ratios (ORs). Risk of bias was assessed with ROBINS-E. Pooled estimates used inverse-variance random-effects meta-analysis; heterogeneity was quantified with I² and Tau². Five studies met inclusion criteria (3 nationwide cohorts from Denmark/Sweden and 2 nested case-control studies from the UK and Australia). Across cohort studies, implant exposure accounted for 1659,309 person-years with 510 BC events. The largest case-control dataset included 67,470 BC cases. Study-specific adjusted estimates were: Morch 2017 RR 0.93 (95% CI 0.48-1.80), Fitzpatrick 2023 OR 1.22 (0.93-1.60), Hadizadeh 2025 HR 1.22 (1.11-1.35), Hultstrand 2022 IRR 1.22 (0.98-1.52), and Tuesley 2025 OR 1.24 (1.17-1.32). The pooled effect showed higher incident BC risk with implant exposure (OR 1.23, 95% CI 1.19-1.27, p < 0.0001) with no observed heterogeneity (I²=0%; Tau²=0). In contemporary population-based data, progestin-only subdermal implant use is associated with a modest but statistically increase (∼23%) in incident BC risk versus non-use. Given low baseline incidence in younger women, absolute risk impact is likely small, but the signal is decision-relevant for shared contraceptive counseling, particularly in patients with elevated baseline BC risk.
